Acrobiosystems Co

Acrobiosystems Co Deferred Tax Liabilities

The Deferred Tax Liabilities of Acrobiosystems Co (301080.SZ) as of Oct 21, 2026 is 135,400.00 CNY. In the previous year, Deferred Tax Liabilities was 5.09 M CNY — a change of -97.34% (lower).

Deferred Tax Liabilities

135,400.00CNY

YoY

-97.34%

Last updated:

Deferred Tax Liabilities of Acrobiosystems Co is 2024 135,400.00 CNY. Deferred Tax Liabilities of Acrobiosystems Co was 2023 5.09 M CNY. It decreases by -97.34% lower compared to the previous year.

The Acrobiosystems Co Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2022
5.09 M CNY
Jan 1, 2024
135,400.00 CNY
The Acrobiosystems Co Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
135,400.00CNY-97.34%
5.09 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Deferred Tax Liabilities of Acrobiosystems Co is 135,400.00 CNY in 2024.

Deferred Tax Liabilities of Acrobiosystems Co changed from 5.09 M CNY to 135,400.00 CNY, representing a -97.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co